Granted Patent
B2
US 12,478,589 · App. 16/923,938 · Granted Nov 25, 2025
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
Assignee:
The Brigham and Women's Hospital, Inc.
A61K9/5146A61K31/7088A61K38/465A61K45/06A61K47/60A61K47/62A61K47/6935A61K48/0041A61P35/00C12N15/113C12Y301/03048C12N2310/14C12N2310/141C12N2310/351C12N2320/31C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Nanoparticulate pharmaceutical formulations and methods for co-delivery of two or more species of nucleic acids for simultaneous suppression and expression of target genes in a cell, are provided. The nanoparticles encapsulate two or more nucleic acid species. The first nucleic acid suppresses expression of a gene or product thereof, e.g., inhibitory nucleic acid, such as antisense, siRNA, miRNA, Dicer siRNA, piRNA, etc. The second nucleic acid increases expression of, or encodes, an endogenous or exogenous protein or polypeptide, e.g., an mRNA. The first and second nucleic acid species simultaneously target or affect the same or different cellular processes within a cell including communication, senescence, DNA repair, gene expression, metabolism, necrosis, and apoptosis.
Claims (23)
1 . A nanoparticle formulation comprising redox-responsive polymeric nanoparticles encapsulating
an inhibitory functional nucleic acid,
wherein the inhibitory functional nucleic acid reduces or suppresses expression of an immune costimulatory molecule or signal, wherein the inhibitory functional nucleic acid is an inhibitory RNA,
and
a stimulatory nucleic acid species comprising an mRNA which enhances or increases an activity in a cell or encodes a protein or peptide,
wherein the stimulatory nucleic acid species encodes an antigen,
wherein the redox-responsive polymeric nanoparticles comprise a poly(disulfide) polymer comprising a disulfide bond linking two L-cysteine residues.
2 . The nanoparticle formulation of claim 1 ,
wherein the inhibitory functional nucleic acid specifically inhibits or reduces expression of a target gene or product thereof in a cell, and the stimulatory nucleic acid increases or induces expression of an endogenous or heterologous protein or polypeptide.
3 . The nanoparticle formulation of claim 1 , wherein the inhibitory RNA is antisense, siRNA, miRNA, piRNA, Dicer siRNA or shRNA.
4 . The nanoparticle formulation of claim 1 , wherein the immune costimulatory molecule or signal is selected from the group consisting of B7/CD28 family members, Butyrophilins, LAIR Family members, Nectin and Nectin-like Ligand/Receptor co-signaling molecules, ILT/CD85 family proteins, TNF superfamily members, SLAM family members, and TIM family co-Signaling molecules.
5 . The nanoparticle formulation of claim 1 , wherein the immune costimulatory molecule or signal is selected from the group consisting of B7-1/CD80, B7-2/CD86, B7-H2, B7-H3, B7-H4, B7-H6, B7-H7/HHLA2, BTLA, CD28, CD30L, CTLA-4, ICOS, PD-1, PD-L1/B7-H1, PD-L2/B7-DC, PDCD6, TMIGD2/CD28H, VISTA/B7-H5/PD-1H, BTN1A1/Butyrophilin, NTB-A/SLAMF6, SLAM/CD150, TIM-1/KIM-1/HAVCR, TIM-3, TIM-4, CD7, CD160, CD200, CD300a/LMIR1, CD300d/LMIR4, CLECL1/DCAL-1, DAP12, Dectin-1/CLEC7A, DPPIV/CD26, EphB6, Integrin alpha 4 beta 1, Integrin alpha 4 beta 7/LPAM-1, LAG-3, and TSLP R.
6 . The nanoparticle formulation of claim 1 , wherein the antigen is a viral capsid protein from a virus selected from the group consisting of an Adeno-Associated Virus (AAV), a Herpesvirus, a retrovirus and a lentivirus.
7 . The nanoparticle formulation of claim 6 , wherein the viral capsid protein is a VP1, VP2, or VP3 capsid protein from an Adeno-Associated Virus (AAV) subtype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAV10.
8 . The nanoparticle formulation of claim 1 , comprising an excipient for administration to an individual in need thereof.
9 . The nanoparticle formulation of claim 8 , wherein the nanoparticles have a diameter of between about 10 nm and about 500 nm, inclusive.
10 . The nanoparticle formulation of claim 1 , wherein the nanoparticles comprise one or more lipids in combination with polymer.
11 . The nanoparticle formulation of claim 1 , wherein the nanoparticles further comprise a ligand.
12 . The nanoparticle formulation of claim 11 , wherein the ligand is selected from the group consisting of a targeting ligand, an adhesion ligand, a cell-penetrating ligand, an endosomal-penetrating ligand, and combinations thereof.
13 . The nanoparticle formulation of claim 1 , wherein the L-cysteine based poly(disulfide) polymer is a linear polymer.
14 . The nanoparticle formulation of claim 1 , wherein the L-cysteine based poly(disulfide) polymer is a polyamide.
15 . The nanoparticle formulation of claim 1 , wherein the L-cysteine based poly(disulfide) polymer comprises L-cystine as a recurring unit.
16 . The nanoparticle formulation of claim 1 , wherein the L-cysteine based poly(disulfide) polymer comprises a fatty diacid.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 30, 2020
From: FAROKHZAD, OMID; XU, XIAODING; SHI, JINJUN
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 053356/0192 →
Continuity (3)
Continuation
16470506
Provisional Application
62435171
· Dec 16, 2016
References Cited (202)
US 5034506A
· Summerton
· 1991
[cited by applicant]
US 5142047A
· Summerton
· 1992
[cited by applicant]
US 5166315A
· Summerton
· 1992
[cited by applicant]
US 5217866A
· Summerton
· 1993
[cited by applicant]
US 5356802A
· Chandrasegaran
· 1994
[cited by applicant]
US 5436150A
· Chandrasegaran
· 1995
[cited by applicant]
US 5487994A
· Chandrasegaran
· 1996
[cited by applicant]
US 5506337A
· Summerton
· 1996
[cited by applicant]
US 5521063A
· Summerton
· 1996
[cited by applicant]
US 5527675A
· Coull
· 1996
[cited by applicant]
US 5539082A
· Nielsen
· 1996
[cited by applicant]
US 5571711A
· Van Der Bruggen
· 1996
[cited by applicant]
US 5623049A
· Loebberding
· 1997
[cited by applicant]
US 5683886A
· Van Der Bruggen
· 1997
[cited by applicant]
US 5698685A
· Summerton
· 1997
[cited by applicant]
US 5714331A
· Buchardt
· 1998
[cited by applicant]
US 5736336A
· Buchardt
· 1998
[cited by applicant]
US 5773571A
· Nielsen
· 1998
[cited by applicant]
US 5786571A
· Bethel
· 1998
[cited by applicant]
US 6140081A
· Barbas
· 2000
[cited by applicant]
US 6453242B1
· Eisenberg
· 2002
[cited by applicant]
US 6534261B1
· Cox, III
· 2003
[cited by applicant]
US 6610512B1
· Barbas
· 2003
[cited by applicant]
US 6673545B2
· Faris
· 2004
[cited by applicant]
US 6677157B1
· Cohen
· 2004
[cited by applicant]
US 6699475B1
· Panicali
· 2004
[cited by applicant]
US 6746838B1
· Choo
· 2004
[cited by applicant]
US 6866997B1
· Choo
· 2005
[cited by applicant]
US 7067617B2
· Barbas, III
· 2006
[cited by applicant]
US 8039587B2
· Khan
· 2011
[cited by applicant]
US 8062891B2
· Khan
· 2011
[cited by applicant]
US 8133733B2
· Khan
· 2012
[cited by applicant]
US 20040197892A1
· Moore
· 2004
[cited by applicant]
US 20070154989A1
· Barbas, III
· 2007
[cited by applicant]
EP 2742944
· 2014
[cited by applicant]
GB 2241703
· 1991
[cited by applicant]
WO 9640039
· 1996
[cited by applicant]
WO 9853059
· 1998
[cited by applicant]
WO 0050900
· 2000
[cited by applicant]
WO 0244321
· 2002
[cited by applicant]
WO 2003016496
· 2003
[cited by applicant]
WO 2004058801
· 2004
[cited by applicant]
WO 2009114487
· 2009
[cited by applicant]
WO 2010056143
· 2010
[cited by applicant]
WO 2011072246
· 2011
[cited by applicant]
WO 2013103972
· 2013
[cited by applicant]
WO 2013176772
· 2013
[cited by applicant]
WO 2014018423
· 2014
[cited by applicant]
WO 2014047350
· 2014
[cited by applicant]
WO WO2016044663A1
· 2016
[cited by examiner]
WO 2016179001
· 2016
[cited by applicant]
Abrams, et al., “Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment.”, Molecular Therapy, 18(1):171-80 (2010).
[cited by applicant]
Adema, et al., “Molecular characterization of the melanocyte lineage-specific antigen gp100”,J. Biol. Chem., 269(31):20126-33 (1994).
[cited by applicant]
Akinc, et al., “A combinatorial library of lipid-like materials for delivery of RNAi therapeutics”, Nat. Biotechnol., 2(5):561-9 (2008).
[cited by applicant]
Alfthan, et al., “Elevation of free ß subunit of human choriogonadotropin and core ß fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease”, Cancer Res., 5…
[cited by applicant]
Ando, et al., “Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells”, Int. J. Cancer, 40:12-17 (1987).
[cited by applicant]
Araki, et al., “mTOR regulates memory CD8 T cell differentiation”, Nature, 460(7251):108-112 (2009).
[cited by applicant]
Assumpção, et al., “The role of piRNA and its potential clinical implications in cancer”, Epigenomics, 7(6):975-84 (2015).
[cited by applicant]
Balkwill, et al., “The tumor microenvironment at a glance”, J Cell Sci,* 125(23):5591-6 (2012).
[cited by applicant]
Barnd, et al., “Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells”, PNAS, 86(18):7159-63 (1989).
[cited by applicant]
Bartel, et al., “MicroRNAs: genomics, review biogenesis, mechanism, and function”, Cell, 116:281-97 (2004).
[cited by applicant]
Bast, et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer”, N. Eng. J. Med., 309:883-7 (1983).
[cited by applicant]
Bernstein, et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference”, Nature, 409:363-6 (2001).
[cited by applicant]
Bertrand, et al., “Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology”, Adv Drug Deliv Rev, 66:2-25 (2014).
[cited by applicant]
Braasch, et al., “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA”, Chem. Biol., 8(1):1-7 (2001).
[cited by applicant]
Brown, et al., “Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies”, J. Immunol., 127:539-46 (1981).
[cited by applicant]
Buckley, et al., “Proresolving lipid mediators and mechanisms in the resolution of acute inflammation”, Immunity. 40(3):315-27 (2014).
[cited by applicant]
Burnett, “Current progress of siRNA/shRNA therapeutics in clinical trials”, Biotechnol. J., 6:(9)1130-46 (2011).
[cited by applicant]
Cermak, et al., “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting”, Nucl. Acids Res., 39(12):1-11 (2011).
[cited by applicant]
Chan, et al., “Spatiotemporal controlled delivery of nanoparticles to injured vasculature”, PNAS, 107:2213-8 (2010).
[cited by applicant]
Chang, et al., “Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium”, Cancer Res., 52:181-6 (1992a).
[cited by applicant]
Chang, et al., “Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas”, Int. J. Cancer, 51(4):548-54 (1992c).
[cited by applicant]
Chang, et al., “Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium”, Int. J. Cancer, 50(3):373-81 (1992b).
[cited by applicant]
Chang, et al., “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers”, PNAS, 93:136-40 (1996).
[cited by applicant]
Chen, et al., “Construction of surfactant-like tetra-tail amphiphilic peptide with RGD ligand for encapsulation of porphyrin for photodynamic therapy”, Biomaterials, 32(6):1678-84 (2011).
[cited by applicant]
Chen, et al., “Multi-functional envelope-type nanoparticles assembled from amphiphilic peptidic prodrug with improved anti-tumor activity”, ACS Appl Mater Interfaces, 6 (1):593-8 (2014).
[cited by applicant]
Cheng, et al., “Multifunctional triblock copolymers for intracellular messenger RNA delivery”, Biomaterials, 33(28):6868-76 (2012).
[cited by applicant]
Chowdhury, et al., “Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity”, PNAS, 95(…
[cited by applicant]
Cong, “Multiplex genome engineering using CRISPR/Cas systems”, Science, 15:339(6121):819-23 (2013).
[cited by applicant]
Cook, et al., “Cellular Glutathione and Thiol Measurements from Surgically Resected Human Lung Tumor and Normal Lung Tissue”, Cancer Res, 51:4287-94 (1991).
[cited by applicant]
Cooray, et al., “Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses”, PNAS; 110:18232-7 (2013).
[cited by applicant]
Costin, et al., “Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein”, Virol. J., 4:123 (2007).
[cited by applicant]
Cougot, et al., “Cap-tabolism'.”, Trends Biochem. Sci., 29(8):436-44 (2004.).
[cited by applicant]
Czech, et al., “One Loop to Rule Them All: The Ping-Pong Cycle and piRNA-Guided Silencing”, Trends Biochem. Sci., S0968-0004(15)00258-3 (2016).
[cited by applicant]
Datta, et al., “Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction”, J. Clin. Oncol., 12:475-82 (1994).
[cited by applicant]
De Fougerolles, “Interfering with disease: a progress report on siRNA-based therapeutics”, Nat. Rev. Drug Discov, 6(6):443-53 (2007).
[cited by applicant]
Dhar, et al., “Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles”, PNAS, 105(45):17356-61 (2008).
[cited by applicant]
Disis, et al., “Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer”, Canc. Res., 54:16-20 (1994).
[cited by applicant]
Dissmeyer, et al., “PROTEOSTASIS: A European Network to Break Barriers and Integrate Science on Protein Homeostasis”, Trends Biochem Sci., 44(5):383-7 (2019).
[cited by applicant]
Dominsnka, et al., “Breaking Down the Barriers: siRNA Delivery and Endosome Escape”, J. Cell Science, 123:1183-1189 (2010).
[cited by applicant]
Elango, et al., “Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector”, Biochim. Biophys. Res. Commun., 330:958-66 (2005).
[cited by applicant]
Elbashir, et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs”, Genes Dev., 15:188-200 (2001).
[cited by applicant]
Farokhzad, et al., “Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy in vivo”, Proceedings of the National Academy of Sciences, 103(16):6315-6320 (2006).
[cited by applicant]
Fiore, et al., “Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor”, J. Exp. Med., 180:253-60 (1994).
[cited by applicant]
Fire, et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans”, Nature, 391:806-11 (1998).
[cited by applicant]
Fischer, et al., “RNAi, a New Therapeutic Strategy Against Viral Infection”, Cell Research, 14:460-466 (2004).
[cited by applicant]
Fredman, et al., “Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice”, Sci Transl Med., 7(275): 275ra20 doi:10.1126/scitranslmed.aaa10…
[cited by applicant]
Gebauer, et al., “Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance”, Anticancer Res., 17(4B):2939-42 (1997).
[cited by applicant]
Getts, et al., “Have we overestimated the benefit of human(ized) antibodies”, MAbs, 2(6):682-4 (2010).
[cited by applicant]
Gold, et al., “Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques”, J. E.9-62 (1985).
[cited by applicant]
Gonzalez, et al., “Viroporins”, FEBS Lett. 552, 28-34 (2003).
[cited by applicant]
Grinstein, et al., “Regulation of cytoplasmic pH in phagocytic cell function and dysfunction”, Clin. Biochem. 24:241-7 (1991).
[cited by applicant]
Guo, et al., “Recent advances in nonviral vectors for gene delivery”, Acc Chem Res., 45(7):971-9 (2012).
[cited by applicant]
Hammond, et al., “An RNA-directed nuclease mediates post-transcriptional gene silencing in
[cited by applicant]
Hannon, “RNA interference”, Nature, 418:244-51 (2002).
[cited by applicant]
Hasturk, et al., “RvE1 protects from local inflammation and osteoclast—mediated bone destruction in periodontitis”, FASEB J., 20:401-3 (2006).
[cited by applicant]
Hatakameya, et al., A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release, 139:127-32 (2009).
[cited by applicant]
Hatakeyama, et al., “Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid”, Gene Ther., 14:68-77 (2007).
[cited by applicant]
Haworth, et al., “Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation”, Nat. Immunol., 9:873-9 (2008).
[cited by applicant]
Hirokawa, et al., “Neuroblastoma in an adult with a high serum level of carbohydrate antigen, CA125: report of a case”, Surg. Today, 28:349-54 (1998).
[cited by applicant]
Hoon, et al., “Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells”, Int. J. Cancer, 43:857-62 (1989).
[cited by applicant]
Horton, et al., “Mitochondria-Penetrating Peptides”, Chem. Biol., 15(4):375-82 (2008).
[cited by applicant]
International Search Report for corresponding PCT application PCT/US2017/067090 dated Apr. 3, 2018.
[cited by applicant]
Islam, et al., “Biomaterials for mRNA delivery”, Biomater. Sci. 3:1519-33 (2015).
[cited by applicant]
Israel, et al., “Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen”, Cancer Res, 53(2):227-30 (1993).
[cited by applicant]
Jager, et al., “Antigen-specific immunotherapy and cancer vaccines”, Int. J. Cancer, 106:817-20 (2003).
[cited by applicant]
Jinek, et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity”, Science, 337(6096):816-21 (2012).
[cited by applicant]
Kamaly, et al., “Targeted Interleukin-10 Nanotherapeutics Developed With a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis”, ACS Nano, 10:5280-5292 (2016).
[cited by applicant]
Kato, et al., “Acidic extracellular microenvironment and cancer”, Cancer Cell Intl, 13(89):1-8 (2013).
[cited by applicant]
Kawakami, et al., “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor”, PNAS, 91:3515-9 (1994).
[cited by applicant]
Kelley, et al., “Development of Novel Peptides for Mitochondrial Drug Delivery: Amino acids Featuring Delocalized Lipophilic Cations”, Pharm Res., (2011).
[cited by applicant]
Kennedy, et al., “A role for antibodies in tumor immunity”, Int. Rev. Immunol., 22:141-72 (2003).
[cited by applicant]
Kim, et al., “Chimeric restriction endonuclease”,. PNAS. 91:883-7 (1994a).
[cited by applicant]
Kim, et al., “Insertion and Deletion Mutants of Fokl Restriction Endonuclease”, J. Biol. Chem., 269:31978-82 (1994b).
[cited by applicant]
Kim, et al., “Targeted delivery of siRNA to macrophages for anti-inflammatory treatment”, Molecular Therapy, 18(5):993-1001 (2010).
[cited by applicant]
Knop, K et al., “Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives”, Chem Int Ed, 49(36):6288-308 (2010).
[cited by applicant]
Kraus, et al., “Implications of acidic tumor microenvironment for neoplastic growth and cancer treatmeAngew nt: a computer analysis”, Tumour Biol, 17:133-54 (1996).
[cited by applicant]
Krishnamoorthy, et al., “Resolvin D1 Binds human Phagocytes With evidence for Proresolving Receptors”, Proc. Natl. Acad. Sci. USA., 107:1660-1665 (2010).
[cited by applicant]
Kudoh, et al., “Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma”, Gynecol. Obstet. Invest., 47:52-7 (1999).
[cited by applicant]
Kwon, et al., “Application of an HIV gp41-derived peptide for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles”, Bioconjugate Chem., 19:920-7 (2008).
[cited by applicant]
Lardner, et al., “The effects of extracellular pH on immune function”, J Leukoc Bio, 69(4):522-30 (2001).
[cited by applicant]
Laroui, et al., “Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles”, Mol Ther; 22(1):69-80 (2014).
[cited by applicant]
Lehmann, et al., “Discrimination between Benign and Malignant Cells of Melanocytic Lineage by Two Novel Antigens, a Glycoprotein with a Molecular Weight of 113,000 and a Protein with a Molecular Weight of 76,000”, Cance…
[cited by applicant]
Lehmann, et al., “MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily”, PNAS, 86:9891-5 (1989).
[cited by applicant]
Leuschner, et al., “Therapeutic siRNA silencing in inflammatory monocytes in mice”, Nature Biotechnol, 29(11):1005-10 (2011).
[cited by applicant]
Li, et al. “Functional domains in Fok I restriction endonuclease”, PNAS, 89:4275-9 (1992).
[cited by applicant]
Li, et al., “Alteration of the cleavage distance of Fok I restriction endonuclease by insertion mutagenesis”, PNAS, 90:2764-8 (1993).
[cited by applicant]
Lim, et al., “Controlled bioactive nanostructures from self-assembly of peptide building blocks”, Angew Chem Int Ed, 46:9011-14(2007).
[cited by applicant]
Lloyd, et al., “Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule”, Int. J. Canc., 71:842-50 (1997).
[cited by applicant]
Love, et al., “Lipid-like materials for low-dose, in vivo gene silencing”, PNAS; 107(5):1864-9 (2010).
[cited by applicant]
Mahmoodzadeh, et al., “Induction of tolerogenic murine dendritic cells by downregulating the co-stimulatory molecule of CD40 using lentivirus vector”, Journal of Zanjan University of Medical Sciences and Health Services…
[cited by applicant]
Martinez, et al., “Single-stranded antisense siRNAs guide target RNA cleavage in RNAi”, Cell, 110:563-74 (2002).
[cited by applicant]
McManus, et al., “Human chorionic gonadotropin in human neoplastic cells”, Cancer Res., 36:3476-81 (1976).
[cited by applicant]
Meier, et al., “Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery”, Anticancer Res., 17(4B):2945-7 (1997).
[cited by applicant]
Miller, et al., “A TALE Nuclease Architecture for Efficient Genome Editing”, Nature Biotechnol., 29:143 (2011).
[cited by applicant]
Murphy, et al., “Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen”, Cancer, 83(11):2259-69 (1998).
[cited by applicant]
Napoli, et al., “Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans”, Plant Cell, 2:279-89 (1990).
[cited by applicant]
Natali, et al., “Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance”, Cancer, 59:55-63 (1987).
[cited by applicant]
Nykanen, et al., “ATP requirements and small interfering RNA structure in the RNA interference pathway”, Cell, 107:309-21 (2001).
[cited by applicant]
Oliveira, et al., “Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes.”, Int. J. Pharm. 331:211-4 (2007).
[cited by applicant]
Opal, et al., “Anti-inflammatory cytokines”, Chest, 117(4): 1162-72 (2000 ).
[cited by applicant]
Pascolo, “Vaccination with messenger RNA (mRNA)”, Handb. Exp. Pharmacol., 183: 221-35 (2008).
[cited by applicant]
Pauley, et al., “RNAi Therapeutics in Autoimmune Disease”, Pharmaceuticals, 6(3):287-94 (2013).
[cited by applicant]
Pearce, et al., “Enhancing CD8-T cell Memory by Modulating Fatty Acid Metabolism”, Nature, 460:103-107 (2009).
[cited by applicant]
Perretti, et al., “Annexin A1 and glucocorticoids as effectors of the resolution of inflammation”, Nat. Rev. Immunol., 9:62-70 (2009b).
[cited by applicant]
Perretti, et al., “Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor”, Nat. Med, 8:1296-1302 (2002).
[cited by applicant]
Perretti, et al., “Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics”, Br. J. Pharmacol .; 158:936-46 (2009a).
[cited by applicant]
Plowman, et al., “Heregulin induces tyrosine phosphorylation of HER4/p180erbB4”, Nature, 366:473-5 (1993).
[cited by applicant]
Ponnappa, “siRNA for inflammatory diseases”, Curr Opin Investig Drugs., 10(5):418-24 (2009).
[cited by applicant]
Priya, et al., “Smart polymers for the controlled delivery of drugs—a concise overview”, Acta Pharma. Sinica B, 4(2):120-7 (2014).
[cited by applicant]
Rose, et al., “Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence”, PNAS, 83:1261-5 (1986).
[cited by applicant]
Sarandakou, et al., Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. Eur. J. Gynaecol. Oncol., 19:73+7 (1998).
[cited by applicant]
Sarandakou, et al., “Vaginal fluid and serum CEA, CA125 and SCC in normal conditions and in benign and malignant diseases of the genital tract”, Acta Oncol., 36:755-9 (1997).
[cited by applicant]
Scanlan, et al., “The cancer/testis genes: Review, standardization, and commentary”,. Cancer Immun., 4:1-15 (2004).
[cited by applicant]
Semple, et al., “Rational design of cationic lipids for siRNA delivery”, Nat. Biotechnol., 28(2):172-6 (2010).
[cited by applicant]
Stefanadis, Increased temperature of malignant urinary bladder tumors in vivo: the application of a new method based on a catheter technique JCO, 19(3):676-81 (2001).
[cited by applicant]
Stepinski, et al., “Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG”, RNA, 7:1468-95 (2001).
[cited by applicant]
Sterchak, et al., “Uncharged stereoregular nucleic acids analogs. 1. Synthesis of a cytosine-containing oligomer with carbamate internucleoside linkages”, Organic Chem., 52:4202 (1987).
[cited by applicant]
Sugahara, et al., “Tissue-penetrating delivery of compounds and nanoparticles into tumors”, Cancer Cell, 16:510-20 (2009).
[cited by applicant]
Tabas, et al., “Anti-inflammatory therapy in chronic disease: challenges and opportunities”, Science. 339(6116):166-72 (2003).
[cited by applicant]
Tan, et al., “RNAi, a new therapeutic strategy against viral infection”, Cell Research, 14, 460-6 (2004).
[cited by applicant]
Topalian, et al., “Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene”, PNAS, 91:9461-5 (1994).
[cited by applicant]
Towbridge, “Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin”, PNAS, 78(5):3039-43 (1981).
[cited by applicant]
Traverso, et al., “Role of Glutathione in Cancer Progression and Chemoresistance”, Oxidative Medicine and Cellular Longevity, vol. 2013:972913 10 pages (2013).
[cited by applicant]
Tsuchida, et al., “Gangliosides of human melanoma: GM2 and tumorigenicity”, J. Natl. Cancer, 78:55-60 (1987b).
[cited by applicant]
Tsuchida, et al., “Gangliosides of human melanoma”, J. Natl. Cancer, 78:45-54 (1987a).
[cited by applicant]
Turnquist, et al., “Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance”, J Immunol. 17…
[cited by applicant]
Urano, et al., “Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes”, Nat. Med., 15:104-109 (2009).
[cited by applicant]
Van den Bruggen, et al., “A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma”, Science, 254:1643-7 (1991).
[cited by applicant]
Vijayasardahi, et al., “The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product”, J. Exp. Med., 171:1375-80 (1990).
[cited by applicant]
Vranic, et al., “Deciphering the mechanisms of cellular uptake of engineered nanoparticles by accurate evaluation of internalization using imaging flow cytometry”, Particle and Fibre Toxicology, 10(2):1-16 (2013).
[cited by applicant]
Wagner, et al., “Targeting of Polyplexes: Toward Synthetic Virus Vector Systems”, Adv. Gen., 53:333-354 (2005).
[cited by applicant]
Walker, et al., “Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors”, Cancer Res., 72(3):636-44 (2012).
[cited by applicant]
Wang, et al., “A Broad Nanoparticle-Based Strategy for tumor Imaging by Nonlinear Amplification of Microenvironment Signals”, Nat. Mater., 13:204-212 (2014).
[cited by applicant]
Weber, et al., “Tumor immunity and autoimmunity induced by immunization with homologous DNA”, J. Clin. Invest, 102:1258-64 (1998).
[cited by applicant]
Weide, “Results of the first phase I/II clinical vaccination trial with direct injection of mRNA”, J. Immunother., 31(2):180-8 (2008).
[cited by applicant]
Whitehead, et al., “Knocking Down Barriers: Advances in siRNA Delivery”, Nat. Rev. Drug Discovery, 8(2), 129-138 (2009).
[cited by applicant]
Whitehead, et al., “Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity”, Nat. Commun., 5:4277doi: 10.1038/ncomms5277 (2014).
[cited by applicant]
Xu, et al., “Enhancing Tumor Cell response to Chemotherapy Through Nanoparticle-Mediated Codelivery of siRNA and Cisplatin Prodrug”, Proc. Natl. Acad. Sci. USA, 110:18638-18643 (2013).
[cited by applicant]
Xu, et al., “mTOR, linking metabolism and immunity.”, Semin Immunol. 24(6):429-35(2012).
[cited by applicant]
Yamaguchi, et al., “Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis”, Br. J. Cancer, 60:382-4 (1989).
[cited by applicant]
Yoshimura, et al., “Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer”, Cancer, 73:2745-52 (1994a).
[cited by applicant]
Yoshino, et al., “Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer”, J. Immunol., 152:2393 (1994b).
[cited by applicant]
Yousif, et al., “Targeting Mitochondria with Organelle□Specific Compounds: Strategies and Applications”, Chembiochem., 10(13):1939-50 (2009).
[cited by applicant]
Yu, et al., “Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery”, ACS Nano, 5:9246-55 (2011).
[cited by applicant]
Zhou, et al., “Tunable, Ultrasensitive pH□Responsive Nanoparticles Targeting Specific Endocytic Organelles in Living Cells”, Angewandte Chemie Int Ed, 50:6109-14 (2011).
[cited by applicant]
Zhu, et al., “Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment”, Proceedings of the National Academy of Sciences USA, 112(25):7779-7784 (2015).
[cited by applicant]